COMMUNIQUÉS West-GlobeNewswire

NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
31/03/2025
Conférence téléphonique et diffusion en direct sur Internet le jeudi 3 avril 2025 à 14 h 00 CEST / 8 h 00 EDT PARIS et CAMBRIDGE, Mass., 31 mars 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la [...]
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
31/03/2025
BASEL, Switzerland, March 31, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV [...]
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
31/03/2025
Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare [...]
Valneva soumet à la MHRA une demande d’élargissement de l’indication aux adolescents pour son vaccin contre le chikungunya IXCHIQ®
31/03/2025
Saint Herblain (France), le 31 mars 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui avoir soumis une demande d’élargissement de l’indication de son [...]
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
31/03/2025
After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of Novartis Karen Hale to drive the next phase of enterprise [...]
Opthea Announces Decision to Discontinue Wet AMD Trials
31/03/2025
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to [...]
First Three Children to Commence Treatment With Ryoncil®
31/03/2025
United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for [...]
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
30/03/2025
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
30/03/2025
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas [...]
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
29/03/2025
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75 years old compared [...]
ProDentim Reviews (EXPOSED): Why 75,000+ Americans Are Replacing Mouthwash with This ProDentim Chewable Tablet
29/03/2025
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- ProDentim reviews In the fast-growing realm of oral health [...]
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29/03/2025
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1 . Data were presented [...]
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
29/03/2025
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a [...]
NeuroQuiet Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness & Safety
29/03/2025
VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a market flooded with hearing supplements and cognitive enhancers, NeuroQuiet has quickly risen to prominence. Over 30,000+ users have already [...]
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
29/03/2025
Ozempic ® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD) in the phase 3 STRIDE trial 1 . Data were presented at the American College of Cardiology' [...]
Best Legal Steroids for Bulking and Muscle Growth 2025 - Buy Steroid Alternatives From CrazyBulk
29/03/2025
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- Use D-Bal to pack on serious muscle and boost your strength in 2025. Using the best legal steroid for bulking and muscle growth can make all the difference in achieving [...]
Legal Steroids For Muscle Growth 2025: Best Steroids For (Bodybuilding & Bulking) By CrazyBulk in USA
29/03/2025
NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- While there is a huge range of steroids available in the market, it is very difficult to know which can work the best for your muscle growth . Choosing the right steroids is [...]
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
29/03/2025
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
29/03/2025
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to [...]

Pages